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ABSTRACT
Stunting is associated with cognitive impairment and later chronic disease. Previous trials to prevent stunting have had little effect, and no trials
seem to have provided larger amounts of energy and high-quality proteins to already stunted children. We aimed to assess the effects of milk
protein (MP) and whey permeate (WP) in large-quantity lipid-based nutrient supplements (LNS-LQ), among stunted children, on linear growth and
child development. This was a randomized, double-blind, 2-by-2 factorial trial. Stunted children aged 12–59 mo from eastern Uganda (n = 750)
were randomly assigned to receive 100 g LNS-LQ with or without MP and WP (n = 4 × 150) or no supplement (n = 150) for 3 mo. The primary
outcomes were change in knee-heel and total length. Secondary outcomes included child development, body composition, anthropometry, and
hemoglobin. Micronutrient status, intestinal function, and microbiota were also assessed. Our findings will contribute to an understanding of the
role of milk ingredients and LNS in linear catch-up growth. This trial was registered at www.isrctn.com as ISRCTN13093195. Curr Dev Nutr
2021;5:nzab067.
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Introduction
Globally, 144 million children under the age of 5 y are classified as
stunted, having a length- or height-for-age z score (HAZ) of less than −2
(1). Stunting is associated with adverse short- and long-term health out-
comes. It is associated with delayed cognitive development, increased
morbidity and mortality (2), poor schooling performance (3, 4), and
later with reduced economic productivity (4) and risk of chronic disease
(5, 6). Stunting also contributes to an intergenerational cycle of malnu-
trition and poverty, whereby a child born to a stunted mother is more
likely to be stunted themselves (7).
In the east African region, close to 1 in 3 children under the age
of 5 are stunted (1). High stunting prevalence is experienced in many
low- and middle-income countries and is indicative of exposure to en-
vironments of inadequate care, suboptimal nutrition, and recurrent in-
fections (3, 5, 6). The majority of growth faltering occurs from 3 to 24
mo of age (8). Nutrition interventions to reduce the risk of stunting have
therefore focused on prevention through optimizing maternal and early
infant nutrition (9, 10). These interventions, however, have had little im-
pact on linear growth. This was summarized in a recent meta-analysis,
whereby complementary feeding interventions, in food-insecure set-
tings, improved HAZ by a mere 0.08 overall (10). The lack of effect on
linear growth has been attributed, at least in part, to environmental en-
teric dysfunction (EED) (11, 12). The premise is that frequent exposure
to pathogens in environments with unsafe water and inadequate sanita-
tion and hygiene [water, sanitation, and hygiene (WASH)] encourages a
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state of systemic and intestinal inflammation, as well as morphological
and functional changes to the intestine, which can, in turn, exacerbate
nutrient deficiencies. However, large trials combining comprehensive
WASH interventions with small-quantity lipid-based nutrient supple-
ments (LNS-SQ) reported no effects from the WASH interventions and
only minimal effects from the LNS-SQ (13–17).
While there have been many studies aiming to prevent stunting in
young children, or to improve linear growth in wasted children, this
is to our knowledge, the first trial which provided large-quantity LNS
(LNS-LQ) to children recruited on the basis of stunting. There have
been concerns that supplementation in stunted children will lead to ex-
cessive accretion of fat rather than lean tissue, and therefore increase
the subsequent risk of chronic disease. These concerns, however, are not
substantiated by the evidence. Recent supplementation studies among
children with moderate (18) and severe acute (19) malnutrition have
shown that even those who are also stunted predominantly gain fat-free
mass (20). There is a gap in the evidence, however, as to the extent that
an LNS-LQ or one containing milk protein (MP) will encourage catch-
up growth in already stunted children, and to what extent this impacts
body composition (21–23), mitigates vulnerability to illness, and im-
proves child development and other functional outcomes (23, 24). How-
ever, it is possible that nutritional support to stunted children could have
beneficial effects even in the absence of linear catch-up growth. We now
know that the co-existence of wasting (low weight-for-height) and lin-
ear growth faltering increases a child’s risk of morbidity and mortality
(25, 26). Moreover, new evidence from a large 40-y cohort study in The
Gambia suggests that stunting not only develops as a chronic condition
but also develops interactively with episodes of wasting as a short-term
adaptation (27, 28).
Previous nutrition interventions may have been limited by an inade-
quate supply of energy and high-quality proteins. Considering this, and
the recent evidence demonstrating that even short children with wast-
ing predominantly gain fat-free mass (20), there is sufficient justification
to assess the effects of an LNS-LQ among stunted children.
Milk intake has long been associated with linear growth (29, 30)
and is suggested to have a stronger effect in low-income compared with
high-income countries (29). However, a new review based on studies
from predominantly high-income countries was not able to confirm an
effect of milk intake on linear growth (31). Several studies have shown
that the addition of milk in supplements to treat acute malnutrition
has had positive effects on body composition, weight gain, recovery,
and anemia (32–37), but limited (18) or no effect in encouraging lin-
ear catch-up growth (32, 35, 38). In studies from low- and high-income
countries, milk intake in children has been associated with improved
lean mass deposition (31), bone-mineral composition (39), and cogni-
tive function (40, 41), benefits that may be experienced to a greater ex-
tent in children exposed to growth-deficient environments (31, 42). Fur-
thermore, the different components of milk may provide unique health
benefits (43). MPs have a complete amino acid profile (31) and are
thought to promote growth by stimulating the growth factors insulin-
like growth factor-I (IGF-I) and insulin (44). On the other hand, whey
permeate (WP) is predominantly composed of lactose and bioavailable
minerals, which may have prebiotic effects (45) as well as a role in bone
mineralization and fat-free mass accretion (46).
In this study, we aimed to assess the individual and combined ef-
fects of MP and WP, provided as part of an LNS-LQ, using a 2 × 2 fac-
FIGURE 1 The primary analysis will compare LNS-LQ with and
without MP and WP in a 2-by-2 factorial design with 150
participants in each given combination. Secondary analysis will
compare all LNS-LQ interventions (n = 600) with the reference
group (family diet, n = 150). LNS-LQ, large-quantity lipid-based
nutrient supplements; MP, milk protein; WP, whey permeate.
torial design, among stunted children. The primary outcome was lin-
ear growth. Secondary outcomes were child development, body com-
position, HAZ, weight-for-age (WAZ), and weight-for-height z scores
(WHZ), weight, midupper arm circumference (MUAC), head circum-
ference, and hemoglobin. In addition, we assessed the main effect of
LNS on these outcomes, irrespective of milk ingredients, as well as the
role of the gut as mediator or modifier of effects.
Methods
The reporting of this protocol followed the Standard Protocol Items:
Recommendations for International Trials (SPIRIT) 2013 checklist.
Trial overview and design
The MAGNUS study (Milk Affecting Growth, Cognition, and the Gut
in Child Stunting) was a randomized, double-blind, 2-by-2 factorial trial
testing the effects of MP and WP in LNS-LQ. An unsupplemented group
was included as a reference. For a 12-wk period between February and
December 2020, 750 Ugandan children classified as stunted received 1
of 4 formulations of LNS-LQ as a daily supplement (n = 4 × 150) or con-
tinued with the family diet (n = 150) (see Figure 1). All caregivers re-
ceived individual nutrition counseling at baseline. All participants were
followed up at the same intervals throughout the intervention period
(see Figure 2). This design will allow us to assess the individual and
combined effects of MP and WP among the 600 children allocated to
LNS, based on the factorial design: If the effects are independent, then
we can compare the 300 given LNS with MP to the 300 given LNS with-
out milk. And likewise, we can compare the 300 given LNS with WP to
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FIGURE 2 MAGNUS data collection time points and visits. Timeline and visit overview for participants enrolled in the study. Phone
follow-up and home visits were carried out as required and thus were unfixed time points. All participants were invited to the same
follow-up visits. Time points were considered valid if taken within ±7 d of baseline, week 2 and week 4, and ±14 d from all other time
points. Hemoglobin was a secondary outcome. LNS-LQ, large-quantity lipid-based nutrient supplement; MAGNUS, Milk Affecting Growth,
Cognition, and the Gut in Child Stunting; MUAC, midupper arm circumference; S, screening in village for referral; T, week of visit from
baseline (T0) to discharge (T12); WASH, water, sanitation, and hygiene.
the 300 given LNS without WP. If the effects are not independent, then
we will compare each of the 4 combinations pairwise. In addition, we
will be able to assess the effect of LNS by comparing the 600 given LNS,
irrespective of milk ingredients, to the 150 given no supplements.
The intervention
LNS are fortified lipid-based pastes that are well adapted for use in
resource-limited settings; they are produced to a high safety standard,
do not require refrigeration or preparation, and are packaged in stan-
dard portion sizes.
Our LNS-LQ supplements, manufactured by Nutriset (Malaunay,
France), varied with respect to the incorporation of WP and MP isolate
(MPI). The MPI contained casein and whey proteins in the same pro-
portions as milk; the lactose and mineral components were removed so
that the MPI was close to 90% protein by weight with a Digestible In-
dispensable Amino Acid Score (DIAAS) of 120 (47). As a comparator to
MPI, soy protein isolate, a high-quality plant protein with a DIAAS of
84, was used (47). WP contained 80–85% lactose and minerals (potas-
sium, phosphorus, magnesium, calcium, sodium, and to a lesser extent
zinc). As a comparator to WP, maltodextrin, a standard ingredient used
in LNS products was used. All formulations were standardized to con-
tain similar proportions of energy, protein, and carbohydrates. The sup-
plements contained a mineral and vitamin mix to improve micronutri-
ent content, and in 2 of the formulations the milk minerals provided by
WP were in addition to the standard amount provided in all formula-
tions (Table 1).
The 600 participants randomly assigned to LNS-LQ received one
100-g sachet (530–535 kcal)/d for 12 wk, distributed every 14 d. Those
randomly assigned to the family diet received laundry soap at each
visit.
Participant recruitment and enrollment
The study was conducted from 2 local community health centers in
Walukuba and Buwenge. All participants were recruited from within the
surrounding district of Jinja, in the Busoga Subregion, eastern Uganda.
Here, the prevalence of child stunting is estimated to be 29%, similar
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Energy, kcal 531 535 530 534
Carbohydrates, g 42 43 42 43
Lactose, g 15.7 0.4 15.3 0
Proteins, g 13.9 13.5 13.9 13.5
Milk proteins, g 7.15 6.75 0.40 0
Vegetable proteins, g 6.75 6.75 13.50 13.50
Lipids, g 33.7 33.7 33.7 33.7
Linoleic acid (C18:2), g 3.0 3.0 3.0 3.0
Linolenic acid (C18:3), g 0.5 0.5 0.5 0.5
Minerals
Calcium, mg 691 594 691 594
Copper, mg 1.65 1.65 1.65 1.65
Iron, mg 12 12 12 12
Iodine, μg 127 113 127 113
Magnesium, mg 199.2 175.8 199.2 175.8
Manganese, mg 1.8 1.8 1.8 1.8
Phosphorus, mg 661 539 661 539
Potassium, mg 1315 985 1315 985
Sodium,2 mg 84 7 156 79
Selenium, μg 30 30 30 30
Zinc, mg 12.5 12.5 12.5 12.5
Vitamins
Vitamin A, mg 619 619 619 619
Vitamin B-1, mg 1.2 1.1 1.2 1.1
Vitamin B-12, μg 3.2 3.0 3.2 3.0
Vitamin B-2, mg 3.1 2.8 2.7 2.4
Niacin, mg 14.9 14.6 14.9 14.6
Pantothenic acid, mg 5.7 4.5 5.7 4.5
Vitamin B-6, mg 2.1 2.0 2.1 2.0
Biotin, μg 74.1 67.6 74.1 67.6
Folic acid, μg 223 223 223 223
Vitamin C, mg 67.9 67.6 67.9 67.6
Vitamin D, μg 16.9 16.9 16.9 16.9
Vitamin E, mg 18 18 18 18
Vitamin K, μg 30 30 30 30
1The same amount of micronutrient premix was used in all formulations. The additional micronutrients provided are from the other ingredients used. LNS-LQ, large-
quantity lipid-based nutrient supplement.
2Soy protein isolate and whey permeate contribute additional sodium.
to the national average (48). To identify stunted children, communi-
ties within the district of Jinja were mobilized by Village Health Teams
for an initial screening for referral. Study staff screened children in the
community for age, stunting, and severe acute malnutrition (SAM). All
children identified as having SAM were referred for appropriate treat-
ment; others who met the inclusion criteria for stunting and age were
invited to one of the study sites for eligibility screening.
At the study sites, children were considered eligible if they were aged
between 12 and 59 mo and had an HAZ of less than −2, according to
the WHO growth standards (49). Children <12 mo old were not eligi-
ble to avoid interfering with breastfeeding. Caregivers had to be living
in the catchment area and willing to return for follow-up visits, and able
to provide written informed consent and agree to both phone follow-
up (if a phone contact was available) and home visits. Children were
excluded if they were identified with SAM according to the WHO clas-
sification (50), had medical complications requiring hospitalization, a
history of allergy to peanuts or milk, obvious disability that impeded
eating capacity, or a disability that impeded the measurement of length
or height. Children were also excluded if they were participating in an-
other study, if the family planned to move away from the catchment area
within 6 mo, if previously enrolled in the MAGNUS study, or if another
child from the same household was already included.
Informed consent
If all eligibility criteria were met, trained staff took the caregiver through
the informed-consent information individually, using the most appro-
priate of 3 commonly spoken languages in the region (English, Lusoga,
or Luganda). The same information was given verbally and in writ-
ing. Caregivers were also taken through a short verbal questionnaire to
ensure that the information provided was adequately understood. Af-
ter necessary clarifications were given, the caregiver consented on be-
half of the participant. If illiterate, a literate witness was present dur-
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ing the informed-consent process. Consenting caregivers were asked
for permission to store 1–2 mL of blood and stool samples from the
participant for future use; this was independent of trial consent. The
caregiver could opt to withdraw consent at any time.
Blinding, randomization, and assignment of interventions
The sachets of LNS-LQ were labeled with a unique 3-letter code that cor-
responded to the different formulations. Two unique codes were given
to each of the 4 formulations and a further 2 codes were created for
the reference group so that 10 unique codes were used in the allocation
sequence list. Only the manufacturer (Nutriset) had access to the blind-
ing code. Two allocation sequence lists, one for each study site, were
computer generated using R (R Foundation for Statistical Computing).
These were generated and sealed by a member of staff at the Univer-
sity of Copenhagen, Denmark, who was otherwise not involved in the
study. Site-stratified, block randomization, with variable block sizes of
10 and 20 were used to allocate the sequential list of ID numbers to the
10 unique codes.
Upon inclusion, administrative staff allocated a unique ID from a se-
quentially ordered list. After completion of baseline activities, the study
pharmacist allocated the intervention according to a hard-copy ran-
dom allocation list. Only the pharmacist had access to the allocation
list, which was checked for each participant, at each visit. Using QR
codes, the pharmacist recorded the code of what was distributed in a
spreadsheet, which was regularly monitored by an independent asses-
sor in Copenhagen. Hard copies of the allocation lists were kept securely
in sealed envelopes at the University of Copenhagen.
Outcome assessors and data analysts were blinded both with respect
to the allocation of the intervention and to the type of ingredients con-
tained in differently coded LNS sachets. Caregivers were blinded with
respect to the type of LNS allocated, since the taste, smell, and appear-
ance of all 4 products were indistinguishable. Caregivers were not, how-
ever, blinded with respect to receiving LNS or not. Only the Data Safety
Monitoring Board, which operated independently of the study, could
choose to break the blinding in order to monitor safety parameters.
Adherence
The LNS was distributed in packs of 14 sachets. To counteract the likeli-
hood of sharing, an additional pack of the same LNS product code was
distributed every 2 wk to caregivers with other children aged between 6
and 59 mo living in the same household. The additional stock provided
to the household increased the likelihood that the participating child
had access to the required daily quota. When collecting new sachets, the
caregiver was requested to return any empty and unused sachets from
the previous 2-wk supply, including those from the additional pack.
Outcomes
Primary outcomes.
The primary outcomes were changes in knee-heel length (mm) and total
length/height (cm) from baseline to 12 wk.
Secondary outcomes.
All secondary outcomes were measured over time from baseline
to 12 wk. Child development was assessed at baseline and at dis-
charge using a locally adapted version of the Malawi Develop-
ment Assessment Tool (MDAT). Anthropometric indices HAZ, WAZ,
and WHZ were assessed as well as weight (g), MUAC (cm), and
head circumference (mm). Body composition was assessed using
bioimpedance and the triceps and subscapular skinfold thicknesses
(mm). The raw data from bioimpedance were used to calculate
the fat mass (FM) (kg), fat-free mass (FFM) (kg), fat mass in-
dex (kg/m2), and fat-free mass index (kg/m2). Hemoglobin concen-




Blood and stool samples were collected at baseline and at week 12. Blood
samples will be analyzed for growth factors (IGF-I and insulin), mark-
ers of micronutrient status [i.e., iron (ferritin, soluble transferrin re-
ceptor), folate (serum folate), vitamin B-12 (cobalamin, methylmalonic
acid), and vitamin A (retinol binding protein)], markers of systemic in-
flammation [C-reactive protein and α1-acid glycoprotein (AGP)], and
markers of intestinal function (citrulline), together with other amino
acids. Stool samples will be analyzed for markers of intestinal inflam-
mation [myeloperoxidase (MPO), neopterin (NEO)] and function (α1-
antitrypsin (AAT)] and the gut microbiota.
Safety, morbidity, and loss to follow-up.
Data will be reported on the proportion of children who, during the in-
tervention period, deteriorated to moderate acute malnutrition or SAM
according to the WHO classifications (49). The proportion of parti-
cipants who died during the study period will be reported, as well as
the number of morbidity episodes including the duration and severity
of the illness. Finally, the number of children who were lost to follow-
up will be reported. Caregivers were called with reminders to attend
upcoming or missed appointments. Loss to follow-up was defined as
those who had not returned for the 12-wk follow-up visit by 14 wk post-
inclusion.
Baseline participant characteristics.
Additional information collected at baseline included demographics, a
dietary intake assessment, and a WASH assessment taken at the initial
home visit.
Measurements
Time points for each measurement are shown in Figure 2.
Anthropometrics.
Knee-heel length was measured using a digital caliper with a resolution
of 0.01 mm (Mitutoyo) mounted with knee and heel caps, cast in hard
plastic. The distance between the knee (from the lateral condyle) and the
heel (calcaneus) was measured 5 times consecutively on the left leg while
the child was seated with both legs hanging over the edge of a table or the
caregiver’s lap. All other anthropometric measurements were repeated
in triplicate. Participant length and height measurements were taken us-
ing a wooden Shorrboard (Weight and Measure), ensuring 4 points of
contact with repositioning between measurements. Maternal height was
measured using a fixed wall stadiometer (SECA 206). The weights of
the mother and participant were measured using an electronic double-
weighing scale (SECA 876). Head circumference, MUAC, and skin-
fold thickness were measured using a windowed, nonelastic head cir-
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cumference tape (SECA 212); a nonelastic MUAC tape (UNICEF SD);
and a Harpenden skinfold caliper (Baty International), respectively.
Height or length, weight, MUAC, and head circumference were mea-
sured according to accepted international standards for anthropometric
measurement (51). Skinfold thicknesses were measured on the left side,
according to the manufacturer’s instructions. For referral and inclu-
sion, z scores were calculated using the WHO field growth charts. The
WHO Anthro program will be used to calculate z scores for data analysis
(52).
Bioimpedance.
Bioimpedance was measured using the Bodystat 500 (50 kHz) and in
accordance with the manufacturer’s instructions (Bodystat Ltd.). Mea-
surements were taken while the child was lying on his/her back, with
limbs spread apart, preferably at rest and with removal of wet or soiled
diapers. A measure was repeated a minimum of 2 times but up to 3 times
if the child’s positioning or movement rated poorly. Measurements
for impedance, resistance, reactance, and phase angle were recorded.
Using an equation, the raw data will be used to calculate FM and
FFM.
Child development.
Child development officers, trained in use of the MDAT (Manual V06,
March 2018), took the participant through a series of activities adapted
for the Ugandan context. The activities were related to 4 domains of de-
velopment: gross motor, fine motor, language, and social development
(53). The participant was graded as to whether or not he/she could com-
plete each task successfully. The assessment continued until the child
had failed to complete 6 tasks consecutively. At baseline, an interviewer-
administered questionnaire was also used to gather information from
the caregiver about household and family indicators for the support of
child development (54).
Clinical assessment.
A thorough clinical examination was carried out at baseline. It included
rapid tests for HIV and malaria, a thorough medical history with ques-
tions related to signs and symptoms of wasting or hospitalization due
to SAM, and assessment of vital signs (pulse, blood pressure, and respi-
ratory rate). At follow-up visits, a short review was conducted, assess-
ing the most recent medical history, milk intake, and where applicable,
monitoring of adverse events. To maintain blinding, the pharmacist dis-
tributing LNS inquired about adherence and if the caregiver had expe-
rienced problems with the LNS.
Biological sample collection.
Stool samples were collected at 2 time points and stored for later anal-
ysis of markers of gut function and microbiota. If not collected on site,
a sample collection kit was given to caregivers along with specific in-
struction on stool sample collection at home. Collection vials contained
StayRNA (A&A Biotechnology), allowing samples to be stored at room
temperature for up to 5 d after collection. A maximum of 6.0 mL of ve-
nous blood was collected on site at 2 time points. A small amount was
used for rapid tests: HIV status, malaria, and hemoglobin status. The re-
maining sample was processed and stored within hours for later analysis
of selected markers. All biological samples were stored at −20◦C until
delivery to the main storage site in Kampala where they were stored at
−80◦C until they were shipped on dry ice to the University of Copen-
hagen, Denmark, for additional analyses.
Other measurements, baseline questionnaires, and WASH
assessment.
At baseline, the child’s age and birth weight were recorded, wherever
possible, using a birth information card. Information on sociodemo-
graphic characteristics, breastfeeding status, food frequency, and diet
diversity was collected via interviewer-administered questionnaires. At
the baseline home visit, GPS coordinates of the home site location were
collected to facilitate later follow-up. In addition, trained staff con-
ducted a short assessment of observed household WASH characteris-
tics, including water source, access to basic sanitation, and the use of
soap. To minimize response bias, local study staff with a good knowl-
edge of the language and the culture were trained in asking questions to
get as clear and precise answers as possible.
Participant retention, reimbursement, referral, and
withdrawal
If visits were missed and phone contact was unsuccessful, attempts were
made to visit the caregiver’s home. To facilitate attendance, a travel re-
imbursement was provided at each visit to cover the cost of return trans-
port and food while at the clinic visit. Any participants requiring hos-
pital attention were referred for treatment. If a caregiver requested for
their child to stop receiving LNS, this was permitted; however, all in-
cluded participants continued to be followed up for the remainder of the
12-wk intervention period. In case of participant withdrawal, all avail-
able data up to the point of withdrawal were used in data analysis.
Data management
Participant data were collected in a paper case report form and were
double entered using Epidata software (https://www.epidata.dk/) with
inbuilt range checks. The secure electronic data collection platform
REDCap (Open Source; Vanderbilt University) was used to monitor
participant registration and visits but not for primary data collection.
All source data will be kept securely on file for a minimum of 5 y af-
ter completion of the study. Adverse and serious adverse events oc-
curring during the intervention period were recorded and reported to
the sponsor and the institutional review board. Events occurring af-
ter a subject was discontinued from the study were not reported un-
less the investigator suspected that the event was related to the LNS-LQ
intervention.
Sample size calculation
To detect a 0.35-SD or greater difference between any 2 groups, with 5%
significance and 80% power, 129 children were required in each group.
To allow for 10% loss to follow-up, 150 children were included in each
group, based on the 4 combinations of MP and WP. If there were no
interactions between the 2 experimental interventions, 2 groups of 300
children could be compared, enabling differences of 0.24 SD to be de-
tected. In the Treatfood trial (18), the SD of knee-heel length at baseline
was 18.1 mm (18), so that a 0.24-SD difference corresponded to 4.3 mm.
In secondary analysis, to assess the effect of LNS, 600 supplemented
children were compared with 150 unsupplemented children, with the
ability to detect a 0.27-SD difference, corresponding to 4.9 mm.
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Statistical methods
Primary and secondary outcomes will be analyzed using linear
mixed models that account for the correlation between repeated
measurements from the same participant, whereas tertiary outcomes
will be analyzed using ordinary ANCOVA models. In all of these AN-
COVA models, the baseline value will be included as a covariate. Ad-
ditional covariates may be included as appropriate. Results will be re-
ported as estimated differences with corresponding 95% CIs and P val-
ues. A statistical analysis plan was prepared before unblinding of the
trial and uploaded to the ISRCTN registry.
This is an effectiveness trial. Therefore, the primary statistical anal-
ysis will be carried out as intention to treat. In subsequent per-protocol
statistical analysis, participants with major protocol deviations or viola-
tions are excluded.
Ethics approval and consent to participate
The study was conducted in accordance with the ethical principles set
forth in the current version of the Declaration of Helsinki and all ap-
plicable local regulatory requirements. The study was approved by the
School of Medicine Research Ethics Committee at Makerere Univer-
sity and The Ugandan National Council of Science and Technology.
The study also received consultative approval from the Danish National
Committee on Biomedical Research Ethics. The study was initiated
only after approval was given by all aforementioned authorities. Writ-
ten informed consent was obtained from all caregivers who consented
to study participation of the child in their care. The rights, safety, and
well-being of the children involved in the study prevailed over science
and society. Before participant recruitment, the study was registered at
www.isrctn.com as ISRCTN13093195.
Discussion
The findings from the MAGNUS trial will help to clarify to what ex-
tent MP and WP, given in LNS, or the LNS per se, play a role in lin-
ear catch-up growth and benefit functional outcomes such as cognition
and the gut. In this, we will explore to what extent functional benefits
are possible with or without effects on linear growth. Our results will
also contribute to current knowledge on whether stunted children will
predominantly gain lean mass when supplemented with LNS-LQ. Since
our study population is aged between 12 and 59 mo, we will also be ex-
ploring the potential for catch-up growth in children beyond 2 y of age.
The gut is thought to play a role in the pathogenesis of stunting, but
studies aiming to minimize environmental pathogen exposures, and so
reduce the risk of EED, have not seen improvements in linear growth. It
may be that, once damaged, the gut requires larger quantities of essential
nutrients in order to repair and facilitate nutrient absorption. We will
explore whether milk components provided in LNS-LQ can improve
reparation of the gut in already stunted children and to what extent gut
function and inflammation act as mediators and effect modifiers of the
effect of LNS-LQ on linear growth.
The high lactose content in WP may have positive effects on the
microbiota and growth. If this is demonstrated in our study, it may
have implications on the future development of LNS, since WP has
the potential to be used as a nutritious substitute for maltodextrin or
sugar.
This is the first randomized controlled trial we are aware of that ex-
plores the effects of LNS-LQ supplementation in already stunted chil-
dren. The strengths of this study are the randomized 2 × 2 factorial de-
sign, which allows us to assess both the individual and combined effects
of the milk ingredients, as well as the unsupplemented reference group,
allowing us to assess the main effects of LNS per se. It is also a strength
that the study includes several secondary functional outcomes alongside
anthropometrics and body composition, as well as tertiary mechanistic
outcomes. It is a limitation that we are unable to include a longer follow-
up period. A follow-up study of the cohort would be of great benefit to
measure the benefits and chronic disease risks associated with the 12-
wk LNS-LQ supplementation.
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